Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...

Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 years Ongoing investment in ...

Please provide your email address to receive an email when new articles are posted on . Cimerli is a ranibizumab biosimilar. Sandoz will pay $170 million in cash for the biosimilar. Sandoz has signed ...

Sandoz has started construction for a new, state-of-the-art biosimilars production center for sterile product manufacturing in Brnik, Slovenia. This $440 million project brings the company’s total ...

We are initiating coverage on Sandoz SDZ with a fair value estimate of CHF 28.50 per share and a no-moat rating. Sandoz is one of the largest generic pharmaceutical manufacturers in the world, earning ...

BOUCHERVILLE, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti® (denosumab subcutaneous injection, ...

Lupin is partnering with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions. Under the terms of the agreement, Sandoz will ...

Rebecca Guntern, President Europe, Sandoz, said: “Early treatment with disease-modifying therapies can have a significant impact on people living with multiple sclerosis and their potential future ...

Sandoz bought the Cimerli (ranibizumab-eqrn) business from Coherus Biosciences, the companies announced Monday morning. In January, Sandoz and Coherus entered into an agreement on a $170 million cash ...

Basel, July 20, 2023 — Sandoz, a global leader in generic and biosimilar medicines, today announced an investment of approximately USD 90 million at its site in Ljubljana, Slovenia to establish a ...

No-moat Sandoz reported solid second-quarter results that came in higher than our expectations. After updating our model and accounting for time value of money, we raise our fair value estimate to $34 ...